Oxford BioDynamics (LON:OBD) Sets New 1-Year Low – Here’s What Happened

Oxford BioDynamics Plc (LON:OBD)’s stock price reached a new 52-week low on Monday . The company traded as low as GBX 0.23 and last traded at GBX 0.23, with a volume of 14444133 shares. The stock had previously closed at GBX 0.23.

Analyst Upgrades and Downgrades

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Oxford BioDynamics in a research report on Wednesday, October 8th.

Oxford BioDynamics Trading Down 0.9%

The company’s fifty day simple moving average is GBX 0.29 and its 200-day simple moving average is GBX 0.40. The firm has a market capitalization of £9.78 million, a PE ratio of -0.08 and a beta of 0.42. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80.

Oxford BioDynamics (LON:OBD) last released its earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.